Athena Investment Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$997K Sell
831
-450
-35% -$460K 0.59% 41
2026
Q1
$1.18M Hold
1,281
0.61% 41
2025
Q4
$1.38M Sell
1,281
-25
-2% -$23.9K 0.71% 31
2025
Q3
$996K Hold
1,306
0.52% 46
2025
Q2
$1.02M Sell
1,306
-2
-0.2% -$1.55K 0.57% 43
2025
Q1
$1.08M Sell
1,308
-101
-7% -$84K 0.65% 41
2024
Q4
$1.09M Sell
1,409
-4
-0.3% -$3.31K 0.63% 35
2024
Q3
$1.25M Sell
1,413
-9
-0.6% -$8.09K 0.71% 30
2024
Q2
$1.29M Sell
1,422
-66
-4% -$52.8K 0.78% 28
2024
Q1
$1.16M Sell
1,488
-27
-2% -$19.2K 0.69% 33
2023
Q4
$883K Hold
1,515
0.57% 43
2023
Q3
$814K Sell
1,515
-28
-2% -$14.4K 0.58% 42
2023
Q2
$724K Sell
1,543
-20
-1% -$8.39K 0.5% 49
2023
Q1
$537K Hold
1,563
0.39% 57
2022
Q4
$572K Sell
1,563
-57
-4% -$20.2K 0.42% 55
2022
Q3
$524K Sell
1,620
-175
-10% -$55.4K 0.44% 56
2022
Q2
$582K Buy
1,795
+676
+60% +$203K 0.46% 50
2022
Q1
$320K Buy
+1,119
New +$288K 0.25% 88

Other funds holding LLY

Athena Investment Management's LLY Position: Q2 2026 in Review

Athena Investment Management reduced its Eli Lilly (LLY) stake by 35% in Q2 2026, selling an estimated $460K and leaving 831 shares worth $997K. The position accounts for 0.59% of the portfolio, ranked #41.

Athena Investment Management first reported a position in LLY in Q1 2022 and has held it in 18 quarters since. The position peaked at $1.38M in Q4 2025. 4,634 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Athena Investment Management held 831 shares of Eli Lilly worth $997K as of Q2 2026.
  • Athena Investment Management sold 450 Eli Lilly shares in Q2 2026, an estimated $460K.
  • Eli Lilly made up 0.59% of Athena Investment Management's portfolio in Q2 2026, its #41 holding.
  • Athena Investment Management first reported a position in Eli Lilly in Q1 2022 and has held it in 18 quarters since.
  • Athena Investment Management's Eli Lilly position peaked at $1.38M in Q4 2025.
  • 4,634 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Athena Investment Management's 13F filing for Q2 2026, filed 6 Aug 2026.